Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romilkimab in Idiopathic Pulmonary Fibrosis
NCT02345070Phase 2Completed
- Sponsor
- Sanofi
- Start
- May 2015
- Primary completion
- May 2017
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 19
01
Overview
Phase 2, randomised, double-blind trial of romilkimab in idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by Sanofi. Primary endpoint: Absolute Change From Baseline in Percent Predicted Forced Vital Capacity (FVC) at 52 weeks. Started May 2015; status: completed.
02
Drugs
romilkimab
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT02345070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02345070.